Incepta began its operation with a handful of highly skilled and dedicated professionals guided by an able leadership. Proper strategic planning, technical excellence, swift and timely decisions helped us achieve our objectives leading to much faster growth. Incepta was able to anticipate the need of the market and provide the right product at the right time. High focus on R&D investment from the very beginning made possible the introduction of quality products ahead of its competitors in most cases.
Incepta Pharmaceuticals Ltd. is now the 2nd largest company of the country and recognized as the fastest growing of the top five manufacturing company in the country. Established in the year 1999, the company has come a long way. Currently the Zirabo and Dhamrai plant consists of several buildings with state of the art technology. Dedicated cephalosporin manufacturing building, a specialized manufacturing building for the production of lyophilized products, insulin and amino acids and newly built liquid and semisolid manufacturing building and large warehouse is also in operation.
Another multipurpose building for housing the Research & Development operation along with the canteen facility is also there. Currently all the products are coming from the plant at Zirabo. The company now produces almost all types of dosage forms covering nearly all therapeutic area.
Incepta now has one of the largest and competent sales force and large distribution network of its own, operated from 21 different locations throughout the country. A most dynamic skilled and dedicated marketing team comprising of pharmacists and doctors are at the core of the marketing operation. These highly skilled professionals play a crucial role in providing the necessary strategic guideline for the promotion of its product.
Chronology of Events:
Our Growth In Comparison With Local Pharma Market (IMS* Data)
From the very beginning Incepta has focused on launching newer and innovative products. High investment in R&D and advanced technology has allowed the company to launch 429 generics with 783 presentations, 158 of which were introduced “first time in Bangladesh”. Incepta and its sister concerns are now manufacturing Human vaccines, Monoclonal antibodies, Biotech products, Hormones, Natural products, Animal health products, Hygiene products and Hospital devices in wide range of dosage forms. Acceptance of these high quality products led to the company caring 2nd position among Pharma companies within 8 years of starting operation.
|Year||No. of Products||First Ever Product||IMS Rank*|
* Intercontinental Marketing Services (IMS)